Hailin Tang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3931009/publications.pdf

Version: 2024-02-01

46984 82499 6,295 129 47 72 citations h-index g-index papers 137 137 137 8782 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. Journal of Experimental and Clinical Cancer Research, 2017, 36, 145.	3.5	277
2	circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression. Theranostics, 2018, 8, 4003-4015.	4.6	199
3	circFBXW7 Inhibits Malignant Progression by Sponging miR-197-3p and Encoding a 185-aa Protein in Triple-Negative Breast Cancer. Molecular Therapy - Nucleic Acids, 2019, 18, 88-98.	2.3	167
4	miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression. Clinical Cancer Research, 2013, 19, 5602-5612.	3.2	152
5	circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Molecular Cancer, 2019, 18, 23.	7.9	149
6	miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. Journal of Cell Science, 2011, 124, 2997-3005.	1.2	147
7	LGR5 Promotes Breast Cancer Progression and Maintains Stem-Like Cells Through Activation of Wnt/β-Catenin Signaling. Stem Cells, 2015, 33, 2913-2924.	1.4	135
8	Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Management and Research, 2018, Volume 10, 5329-5338.	0.9	124
9	Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. Cancer Letters, 2013, 340, 72-81.	3.2	109
10	The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer. Scientific Reports, 2016, 6, 21735.	1.6	109
11	MiR-185 Targets the DNA Methyltransferases 1 and Regulates Global DNA Methylation in human glioma. Molecular Cancer, 2011, 10, 124.	7.9	106
12	High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. Breast, 2016, 30, 39-46.	0.9	102
13	Direct Quantification of MicroRNA at Low Picomolar Level in Sera of Glioma Patients Using a Competitive Hybridization Followed by Amplified Voltammetric Detection. Analytical Chemistry, 2012, 84, 6400-6406.	3.2	101
14	LINC01638 IncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. Oncogene, 2018, 37, 6166-6179.	2.6	101
15	MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1. PLoS ONE, 2013, 8, e65138.	1.1	100
16	Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Molecular and Cellular Biochemistry, 2013, 382, 103-111.	1.4	97
17	Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Research, 2011, 1390, 21-32.	1.1	94
18	miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 3185-3197.	1.9	93

#	Article	IF	CITATIONS
19	The Role of Circular RNA CDR1as/ciRS-7 in Regulating Tumor Microenvironment: A Pan-Cancer Analysis. Biomolecules, 2019, 9, 429.	1.8	87
20	Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094092.	1.4	86
21	miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Letters, 2015, 357, 384-392.	3.2	85
22	microRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. Molecular and Cellular Biochemistry, 2014, 392, 153-159.	1.4	83
23	miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. Cancer Letters, 2015, 356, 410-417.	3.2	81
24	N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nature Communications, 2022, 13, 2672.	5.8	80
25	The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas. Current Cancer Drug Targets, 2013, 13, 221-231.	0.8	77
26	The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast, 2017, 32, 1-6.	0.9	74
27	Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer. Journal of Hematology and Oncology, 2020, 13, 17.	6.9	74
28	miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget, 2015, 6, 34968-34978.	0.8	72
29	Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of \hat{l}^2 -catenin stabilization in cancer stem cells. Journal of Experimental and Clinical Cancer Research, 2017, 36, 172.	3.5	67
30	Diallyl Disulfide Suppresses SRC/Ras/ERK Signaling-Mediated Proliferation and Metastasis in Human Breast Cancer by Up-Regulating miR-34a. PLoS ONE, 2014, 9, e112720.	1.1	67
31	Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation. Oncotarget, 2015, 6, 9854-9876.	0.8	67
32	miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma. Tumor Biology, 2013, 34, 1793-1800.	0.8	66
33	miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. Journal of Translational Medicine, 2014, 12, 17.	1.8	64
34	miR-185 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer. Molecular and Cellular Biochemistry, 2014, 386, 223-231.	1.4	63
35	Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients. Disease Markers, 2018, 2018, 1-15.	0.6	61
36	MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget, 2015, 6, 20070-20083.	0.8	60

#	Article	IF	CITATIONS
37	SOX2 Promotes Cell Proliferation and Metastasis in Triple Negative Breast Cancer. Frontiers in Pharmacology, 2018, 9, 942.	1.6	59
38	CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression. Epigenomics, 2019, 11, 1163-1176.	1.0	59
39	AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 65.	3.5	58
40	Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. Biomedicine and Pharmacotherapy, 2018, 97, 1275-1281.	2.5	58
41	LRRC4 Inhibits Glioma Cell Growth and Invasion Through a miR-185- Dependent Pathway. Current Cancer Drug Targets, 2012, 12, 1032-1042.	0.8	57
42	Caveolin-1, a stress-related oncotarget, in drug resistance. Oncotarget, 2015, 6, 37135-37150.	0.8	57
43	Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a populationâ€based study. Cancer Medicine, 2018, 7, 922-930.	1.3	57
44	Circular RNA circEPSTI1 accelerates cervical cancer progression via miR-375/409-3P/515-5p-SLC7A11 axis. Aging, 2021, 13, 4663-4673.	1.4	57
45	CircAHNAK1 inhibits proliferation and metastasis of triple-negative breast cancer by modulating miR-421 and RASA1. Aging, 2019, 11, 12043-12056.	1.4	56
46	Adam12 and Inc015192 act as ceRNAs in breast cancer by regulating miR-34a. Oncogene, 2018, 37, 6316-6326.	2.6	55
47	mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK. Oncotarget, 2016, 7, 35188-35198.	0.8	55
48	AFAP1-AS1 Promotes Epithelial-Mesenchymal Transition and Tumorigenesis Through Wnt/ \hat{l}^2 -Catenin Signaling Pathway in Triple-Negative Breast Cancer. Frontiers in Pharmacology, 2018, 9, 1248.	1.6	54
49	Primary tumor resection in stage IV breast cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2018, 44, 1504-1512.	0.5	54
50	circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGF1 and FGF2 expression. Carcinogenesis, 2019, 40, 1469-1479.	1.3	53
51	Multiplexed Electrochemical Detection of MiRNAs from Sera of Glioma Patients at Different Stages via the Novel Conjugates of Conducting Magnetic Microbeads and Diblock Oligonucleotide-Modified Gold Nanoparticles. Analytical Chemistry, 2017, 89, 10834-10840.	3.2	52
52	Metformin mediates induction of miRâ€₹08 to inhibit selfâ€renewal and chemoresistance of breast cancer stem cells through targeting CD47. Journal of Cellular and Molecular Medicine, 2019, 23, 5994-6004.	1.6	52
53	Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis. Annals of Translational Medicine, 2021, 9, 675-675.	0.7	52
54	Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials. PLoS ONE, 2018, 13, e0192464.	1.1	51

#	Article	IF	Citations
55	High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. Journal of Cancer, 2019, 10, 3239-3245.	1.2	49
56	Disturbing miR-182 and -381 Inhibits BRD7 Transcription and Glioma Growth by Directly Targeting LRRC4. PLoS ONE, 2014, 9, e84146.	1.1	49
57	High expression of microRNA-183/182/96 cluster as a prognostic biomarker for breast cancer. Scientific Reports, 2016, 6, 24502.	1.6	47
58	PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a. Journal of Experimental and Clinical Cancer Research, 2017, 36, 129.	3.5	47
59	The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. Journal of Cancer, 2018, 9, 861-871.	1.2	47
60	Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma. Journal of Cancer Research and Therapeutics, 2015, 11, 630-634.	0.3	47
61	The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. Molecular Cancer, 2022, 21, 29.	7.9	47
62	Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis. EBioMedicine, 2021, 63, 103137.	2.7	44
63	miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Research, 2017, 19, 72.	2.2	43
64	Preoperative prediction nomogram based on primary tumor miRNAs signature and clinicalâ€related features for axillary lymph node metastasis in earlyâ€stage invasive breast cancer. International Journal of Cancer, 2018, 142, 1901-1910.	2.3	43
65	Amplified voltammetric detection of miRNA from serum samples of glioma patients via combination of conducting magnetic microbeads and ferrocene-capped gold nanoparticle/streptavidin conjugates. Biosensors and Bioelectronics, 2016, 86, 502-507.	5. 3	41
66	Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer. Journal of Cancer, 2018, 9, 3728-3735.	1.2	39
67	Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer. Cancer Management and Research, 2019, Volume 11, 179-190.	0.9	37
68	Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in tripleâ€negative breast cancer. International Journal of Cancer, 2020, 147, 542-553.	2.3	36
69	ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH. Molecular Cancer, 2015, 14, 84.	7.9	35
70	MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells. Oncotarget, 2015, 6, 7930-7943.	0.8	34
71	Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer. Journal of Cancer, 2016, 7, 2309-2316.	1.2	34
72	LncRNA SNORD3A specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMPS expression. Cell Death and Disease, 2020, 11, 329.	2.7	33

#	Article	IF	Citations
73	New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 9644.	1.8	33
74	Development and validation of a nomogram for predicting survival on the base of modified lymph node ratio in breast cancer patients. Breast, 2017, 33, 14-22.	0.9	31
75	Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study. Frontiers in Oncology, 2020, 10, 580241.	1.3	31
76	Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It. International Journal of Molecular Sciences, 2021, 22, 13335.	1.8	31
77	microRNA-22 acts as a metastasis suppressor by targeting metadherin in gastric cancer. Molecular Medicine Reports, 2015, 11, 454-460.	1.1	30
78	Construction of an immune-related genes nomogram for the preoperative prediction of axillary lymph node metastasis in triple-negative breast cancer. Artificial Cells, Nanomedicine and Biotechnology, 2020, 48, 288-297.	1.9	30
79	SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Carcinogenesis, 2019, 40, 1278-1287.	1.3	29
80	SOX2 Promotes Brain Metastasis of Breast Cancer by Upregulating the Expression of FSCN1 and HBEGF. Molecular Therapy - Oncolytics, 2020, 17, 118-129.	2.0	29
81	The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2339-2345.	1.2	28
82	miRâ€200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 8114-8127.	1.6	28
83	Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling. Current Cancer Drug Targets, 2018, 18, 592-599.	0.8	27
84	Isoliquiritigenin Suppresses EMT-Induced Metastasis in Triple-Negative Breast Cancer through miR-200c/C-JUN/β-Catenin. The American Journal of Chinese Medicine, 2021, 49, 505-523.	1.5	26
85	Identification of a 4â€ <scp>mRNA</scp> metastasisâ€related prognostic signature for patients with breast cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 1439-1447.	1.6	25
86	Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer. Cell Death and Differentiation, 2020, 27, 2066-2080.	5.0	25
87	Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients. Journal of Cancer, 2016, 7, 1747-1754.	1.2	23
88	Melatonin Regulates Breast Cancer Progression by the lnc010561/miR-30/FKBP3 Axis. Molecular Therapy - Nucleic Acids, 2020, 19, 765-774.	2.3	23
89	Isoliquiritigenin Derivative Regulates miR-374a/BAX Axis to Suppress Triple-Negative Breast Cancer Tumorigenesis and Development. Frontiers in Pharmacology, 2020, 11, 378.	1.6	23
90	Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients. PLoS ONE, 2016, 11, e0161902.	1.1	23

#	Article	IF	Citations
91	Diagnostic and prognostic value of serum MACC1 in breast cancer patients. Oncotarget, 2016, 7, 84408-84415.	0.8	21
92	POTEH hypomethylation, a new epigenetic biomarker for glioma prognosis. Brain Research, 2011, 1391, 125-131.	1.1	19
93	Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2017, 15, 210.	0.8	17
94	LCTL Is a Prognostic Biomarker and Correlates With Stromal and Immune Infiltration in Gliomas. Frontiers in Oncology, 2019, 9, 1083.	1.3	16
95	Prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in breast: A meta-analysis of PSM studies. Breast, 2020, 51, 11-20.	0.9	16
96	Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-Î ² - catenin Signaling in Breast Cancer. Current Cancer Drug Targets, 2018, 18, 390-399.	0.8	15
97	F10 gene hypomethylation, a putative biomarker for glioma prognosis. Journal of Neuro-Oncology, 2012, 107, 479-485.	1.4	14
98	Fabrication of multifunctional monometallic nanohybrids for reactive oxygen species-mediated cell apoptosis and enhanced fluorescence cell imaging. Journal of Materials Chemistry B, 2018, 6, 1187-1194.	2.9	14
99	Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 1813-1825.	1.9	13
100	Amplified electrochemical detection of circular RNA in breast cancer patients using ferrocene-capped gold nanoparticle/streptavidin conjugates. Microchemical Journal, 2021, 164, 106066.	2.3	13
101	FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer. Current Cancer Drug Targets, 2018, 18, 382-389.	0.8	13
102	Establishment of a prognostic ferroptosisâ€related gene profile in acute myeloid leukaemia. Journal of Cellular and Molecular Medicine, 2021, 25, 10950-10960.	1.6	13
103	TMPyP Inhibits Amyloid- \hat{l}^2 Aggregation and Alleviates Amyloid-Induced Cytotoxicity. ACS Omega, 2017, 2, 4188-4195.	1.6	12
104	Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: A systematic review and meta-analysis involving 186982 patients. PLoS ONE, 2017, 12, e0173862.	1.1	12
105	ldentification of a prognostic metabolic gene signature in diffuse large Bâ€cell lymphoma. Journal of Cellular and Molecular Medicine, 2021, 25, 7066-7077.	1.6	11
106	Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study. Cancer Control, 2020, 27, 107327482097666.	0.7	11
107	Maackiain Modulates miR-374a/GADD45A Axis to Inhibit Triple-Negative Breast Cancer Initiation and Progression. Frontiers in Pharmacology, 2022, 13, 806869.	1.6	11
108	Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Letters, 2015, 356, 374-381.	3.2	10

#	Article	IF	Citations
109	Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer. PLoS ONE, 2016, 11, e0165133.	1.1	10
110	Determination of the prognostic value of preoperative CA15â€'3 and CEA in predicting the prognosis of young patients with breast cancer. Oncology Letters, 2018, 16, 4679-4688.	0.8	10
111	Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer. Frontiers in Oncology, 0, 12, .	1.3	9
112	Protein phosphorylation networks in spargana of Spirometra erinaceieuropaei revealed by phosphoproteomic analysis. Parasites and Vectors, 2020, 13, 248.	1.0	8
113	Breastâ€conserving therapy shows better prognosis in mucinous breast carcinoma compared with mastectomy: A SEER populationâ€based study. Cancer Medicine, 2020, 9, 5381-5391.	1.3	8
114	The biogenesis, function and clinical significance of circular RNAs in breast cancer. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	8
115	Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer. Current Cancer Drug Targets, 2018, 19, 74-80.	0.8	7
116	Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breastâ€conserving therapy?. Cancer Communications, 2019, 39, 1-12.	3.7	7
117	Hepatitis B virus infection specially increases risk of liver metastasis in breast cancer patients: a propensity-matched analysis. Translational Cancer Research, 2020, 9, 1506-1517.	0.4	6
118	BikDDA, a Mutant of Bik with Longer Half-Life Expression Protein, Can Be a Novel Therapeutic Gene for Triple-Negative Breast Cancer. PLoS ONE, 2014, 9, e92172.	1.1	5
119	Incidence and Survival Outcomes of Breast Cancer with Synchronous Hepatic Metastases: A Population-Based Study. Journal of Cancer, 2018, 9, 4306-4313.	1.2	5
120	Nomogram to Predict Internal Mammary Lymph Nodes Metastasis in Patients With Breast Cancer. Frontiers in Oncology, 2019, 9, 1193.	1.3	5
121	PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097421.	1.4	5
122	Second invasive breast cancers in patients treated with breast-conserving therapy. European Journal of Surgical Oncology, 2021, 47, 2492-2498.	0.5	5
123	Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: A retrospective study. Cancer Biomarkers, 2015, 15, 115-123.	0.8	4
124	Sensitive and simultaneous surface plasmon resonance detection of free and p53-bound MDM2 proteins from human sarcomas. Analyst, The, 2018, 143, 2029-2034.	1.7	4
125	Prognostic value of chronic hepatitis B virus infection in patients with breast cancer in a hepatitis B virus endemic area. Annals of Translational Medicine, 2020, 8, 180-180.	0.7	3
126	Efficient systemic DNA delivery to the tumor by self-assembled nanoparticle. Journal of Nanoparticle Research, 2014, 16, 1.	0.8	2

Hailin Tang

#	Article	IF	CITATIONS
127	Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast. Cancer Medicine, 2017, 6, 2489-2496.	1.3	2
128	Abstract 520: circEPSTI1 as a prognostic marker and mediator of triple-negative breast cancer progression. Cancer Research, 2018, 78, 520-520.	0.4	1
129	Circular RNAs as miRNA sponges in triple-negative breast cancer: a systematic review. Minerva Biotecnologica, 2020, 32, .	1.2	1